Dilution profile // every instrument, one screen, from SEC filings

Greenwich LifeSciences, Inc. (GLSI)

CIK 1799788 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-3 on file 2024-10-07
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 0% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
LOW+14% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
MEDIUM~7.5 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-11-162026-05-26

Latest: 14.7M shares as of May 26, 2026 (10-Q).

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 20,174 underlying shares, as reported Jun 30, 2025 (10-Q).

Reported exercise price: $7.1875 (aggregate figure as tagged; individual tranches vary).

Balance-sheet fair value of warrants: $37,978 as of Jun 30, 2025.

Rough fully diluted estimate: 14.7M = 14.7M O/S + 20,174 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Jun 4, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding14.7MMay 26, 2026
+ Warrants (aggregate, as tagged) (if exercised)20,174Jun 30, 2025
Fully diluted estimate14.7M+0.1% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Oct 7, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 0 executed · 0 registered.

EFFECTIVEOct 17, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDOct 7, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDJun 17, 2024Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJul 12, 2022Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEApr 6, 2022SEC declared a registration effective — selling can beginEFFECT
REGISTEREDApr 1, 2022S-3/A registration — capacity to sell shares, not a sale yetS-3/A
REGISTEREDMar 25, 2022S-3 registration — capacity to sell shares, not a sale yetS-3
UPDATEMar 8, 2021Prospectus update — often a resale registration, not necessarily new capital424B3
EXECUTEDDec 18, 2020Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4
REGISTEREDDec 17, 2020S-1MEF registration — capacity to sell shares, not a sale yetS-1MEF
EFFECTIVEDec 17, 2020SEC declared a registration effective — selling can beginEFFECT
MARKETINGDec 16, 2020Free-writing prospectus — offering being marketedFWP

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full GLSI workspace